Navigation Links
Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
Date:11/21/2007

SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Alliance Pharmaceutical Corp. (OTC Bulletin Board: ALLP). Following a Steering Committee meeting last week in China with its partner Beijing Double-Crane Pharmaceutical Co., Ltd. (Double-Crane), Alliance has updated its clinical development plan for Oxygent(TM) (perfluorochemical [PFC] emulsion) to focus primarily on supporting the initial clinical development of Oxygent in China. The clinical development plan for China is to investigate Oxygent in maintaining hemodynamic stability during major surgery, thereby potentially reducing or avoiding intraoperative transfusions of donor blood in major surgery. In addition, the Phase 2 clinical trial in China will incorporate oxygenation endpoints of postoperative improvement of organ function, such as the gut, heart, brain and kidney. As a result, Alliance will discontinue enrollment in the current French study and evaluate a new protocol to correspond to the China Phase 2 study. Alliance is currently transferring the manufacturing technology to enable Double-Crane to manufacture Oxygent in China. Following the manufacture of clinical supplies in China, Double-Crane plans to submit an IND to the sFDA, which is anticipated to be completed in 2008. Alliance will seek additional funding to support this plan.

About Alliance Pharmaceutical Corp.

Alliance is a development-stage pharmaceutical company that is currently focused on developing its lead product, Oxygent, which is based on its proprietary PFC technology. Oxygent is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

Except for historical information, the matters set forth in this release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth herein. Alliance refers you to cautionary information contained in documents Alliance files with the Securit
'/>"/>

SOURCE Alliance Pharmaceutical Corp.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)... REINACH, Switzerland, November 20 /PRNewswire... that the Anti-infective Drugs Advisory Committee ...s voted 17 to 2 against the,approval of intraveno...t for,the treatment of patients with complicated ...uding those caused by methicillin-resistant Staphy...
(Date:11/20/2008)... LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ ... DSKA), announced today that it has submitted its,...r review under a Special,Protocol Assessment (SPA...tion,(FDA). , Subject to securing an agree...ngle, prospective, double-blind, placebo-controlle...
(Date:11/20/2008)... BOSTON, Nov. 20 PAREXEL...ading global biopharmaceutical services provider, ...ma, Peru to provide regulatory consulting and clin...he Peru office, PAREXEL now has locations througho...in America, which also include Argentina, Brazil, ...
(Date:11/19/2008)... THOUSAND OAKS, Calif., Nov. 19 /PRNewswire-FirstC...he Takeda Oncology Company, a subsidiary of,Taked...y announced that,enrollment in the Phase 3 MONET1...ion with paclitaxel and carboplatin for the first-...ncer (NSCLC) has been temporarily suspended,follo...
Breaking Medicine Technology:Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7High Blood Pressure May Heighten Effects of Alzheimers Disease 934 1High Blood Pressure May Heighten Effects of Alzheimers Disease 934 2Transporters may help delay diabetes related retinal damage 7116 1Transporters may help delay diabetes related retinal damage 7116 2Transporters may help delay diabetes related retinal damage 7116 3Nanotechnology and the media 3A The inside story 1364 1Nanotechnology and the media 3A The inside story 1364 2Promising Data ATIR Studies Presented by NIH Investigators 1980 1Promising Data ATIR Studies Presented by NIH Investigators 1980 2
(Date:11/22/2008)... Open enrollment is now happ...over expenses not covered by Medicare, and may als... consumers are now shopping online for instant quo...ort Collins, CO (PRWEB) November 21, 2008 -- MediG... for Medicare Supplement plans . Medicare Advant...
(Date:11/21/2008)...NGE COUNTY, Calif., Nov. 21 Album ...ting firm, launches a new program offering big bra...have taken the large, expensive ad agency process ...s with a very hands-on approach," says Matt Parker... 2002, combines experience and proven brand-buildi...
(Date:11/21/2008)...s, parents and schools need to work together to st...DAY, Nov. 21 (HealthDay News) -- Behavior that was...ized as bullying. , And as mounting research sh... victim, mental-health professionals, schools, par...ew ways to combat this threatening behavior. ,...
(Date:11/21/2008)... TALLAHASSEE, Fla. -- A Florida State University C...ang has discovered an important new layer of regul... to a greater understanding of the way cancer begi... sciences at the College of Medicine, said the fin... cancer and could lead to the design of new drugs ...
Breaking Medicine News(10 mins):Health News:MediGap Advisors Announces Open Enrollment for Medicare Supplement Plans 2Health News:Album Creative Studios Tailors Big Brand Marketing For Small Businesses 2Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3
...growth of colon polyps to half, it doubles the ris...by two significant studies published in the Aug. 3...e opinions of Bruce M. Psaty, M.D., Ph.D., and Joh...iversity of Washington were also published along w...
... only reverses the arterial dysfunction caused by ...ame arteries compared to before the meal, accordin...dings, reported in the European Journal of Applied...us on the effect food has on the body after the me...
...reas preoperative brain could effectively alter th...pear in the September issue of Radiology, states t...uage areas of the brain with functional magnetic r...e surgeons in pinpointing the brain tumors more ef...
...as challenged the view of The Sterling Council, of...alarm service, which the// Scottish public service...minced words that the ruling is a target at the we...ruly a mockery of the free care provided for the e...
Other Medicine News:Health News:Celebrex- pros and cons 2Health News:A Serving of Exercise After That Saturated Fat 2Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 2Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 3
Bandeau Bra
Bras and Breast Support
Compression Bra
Constructed from soft Shur-grip foam and velcro closure for easy application and - reapplication
Medicine Products: